Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival.

Muntasell A, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D, Costa-García M, Martínez-Garcia M, Menéndez S, Vazquez I, Lluch A, Gonzalez-Perez A, Rovira A, López-Botet M, Albanell J.

Clin Cancer Res. 2019 Mar 1;25(5):1535-1545. doi: 10.1158/1078-0432.CCR-18-2365. Epub 2018 Dec 6.

PMID:
30523021
2.

CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase.

Hernández-Sánchez M, Kotaskova J, Rodríguez AE, Radova L, Tamborero D, Abáigar M, Plevova K, Benito R, Tom N, Quijada-Álamo M, Bikos V, Martín AÁ, Pal K, García de Coca A, Doubek M, López-Bigas N, Hernández-Rivas JM, Pospisilova S.

Leukemia. 2019 Feb;33(2):518-558. doi: 10.1038/s41375-018-0255-1. Epub 2018 Sep 12. No abstract available.

3.

Comprehensive Characterization of Cancer Driver Genes and Mutations.

Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; Cancer Genome Atlas Research Network, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L.

Cell. 2018 Aug 9;174(4):1034-1035. doi: 10.1016/j.cell.2018.07.034. No abstract available.

4.

A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations.

Tamborero D, Rubio-Perez C, Muiños F, Sabarinathan R, Piulats JM, Muntasell A, Dienstmann R, Lopez-Bigas N, Gonzalez-Perez A.

Clin Cancer Res. 2018 Aug 1;24(15):3717-3728. doi: 10.1158/1078-0432.CCR-17-3509. Epub 2018 Apr 17.

5.

Comprehensive Characterization of Cancer Driver Genes and Mutations.

Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; Cancer Genome Atlas Research Network, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L.

Cell. 2018 Apr 5;173(2):371-385.e18. doi: 10.1016/j.cell.2018.02.060. Erratum in: Cell. 2018 Aug 9;174(4):1034-1035.

6.

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations.

Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, Tusquets I, Albanell J, Rodon J, Tabernero J, de Torres C, Dienstmann R, Gonzalez-Perez A, Lopez-Bigas N.

Genome Med. 2018 Mar 28;10(1):25. doi: 10.1186/s13073-018-0531-8.

7.

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing.

Majumder MM, Silvennoinen R, Anttila P, Tamborero D, Eldfors S, Yadav B, Karjalainen R, Kuusanmäki H, Lievonen J, Parsons A, Suvela M, Jantunen E, Porkka K, Heckman CA.

Oncotarget. 2017 May 5;8(34):56338-56350. doi: 10.18632/oncotarget.17630. eCollection 2017 Aug 22.

8.

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.

Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, Ordóñez GR, Rovira J, Clot G, Royo C, Navarro A, Gonzalez-Farre B, Vaghefi A, Castellano G, Rubio-Perez C, Tamborero D, Briones J, Salar A, Sancho JM, Mercadal S, Gonzalez-Barca E, Escoda L, Miyoshi H, Ohshima K, Miyawaki K, Kato K, Akashi K, Mozos A, Colomo L, Alcoceba M, Valera A, Carrió A, Costa D, Lopez-Bigas N, Schmitz R, Staudt LM, Salaverria I, López-Guillermo A, Campo E.

Leukemia. 2018 Mar;32(3):675-684. doi: 10.1038/leu.2017.251. Epub 2017 Aug 14.

9.

Comparison of algorithms for the detection of cancer drivers at subgene resolution.

Porta-Pardo E, Kamburov A, Tamborero D, Pons T, Grases D, Valencia A, Lopez-Bigas N, Getz G, Godzik A.

Nat Methods. 2017 Aug;14(8):782-788. doi: 10.1038/nmeth.4364. Epub 2017 Jul 17.

10.

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.

Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D, Kontro M, Parsons A, Suvela M, Mayoral Safont M, Porkka K, Aittokallio T, Kallioniemi O, McCormack E, Gjertsen BT, Wennerberg K, Knowles J, Heckman CA.

Blood. 2017 Aug 10;130(6):789-802. doi: 10.1182/blood-2016-02-699363. Epub 2017 Jun 15.

PMID:
28619982
11.

CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer.

Griffith M, Spies NC, Krysiak K, McMichael JF, Coffman AC, Danos AM, Ainscough BJ, Ramirez CA, Rieke DT, Kujan L, Barnell EK, Wagner AH, Skidmore ZL, Wollam A, Liu CJ, Jones MR, Bilski RL, Lesurf R, Feng YY, Shah NM, Bonakdar M, Trani L, Matlock M, Ramu A, Campbell KM, Spies GC, Graubert AP, Gangavarapu K, Eldred JM, Larson DE, Walker JR, Good BM, Wu C, Su AI, Dienstmann R, Margolin AA, Tamborero D, Lopez-Bigas N, Jones SJ, Bose R, Spencer DH, Wartman LD, Wilson RK, Mardis ER, Griffith OL.

Nat Genet. 2017 Jan 31;49(2):170-174. doi: 10.1038/ng.3774. No abstract available.

12.

Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia.

Ojamies PN, Kontro M, Edgren H, Ellonen P, Lagström S, Almusa H, Miettinen T, Eldfors S, Tamborero D, Wennerberg K, Heckman C, Porkka K, Wolf M, Kallioniemi O.

Leukemia. 2017 May;31(5):1048-1058. doi: 10.1038/leu.2016.286. Epub 2016 Oct 31.

PMID:
27795554
13.

Rational design of cancer gene panels with OncoPaD.

Rubio-Perez C, Deu-Pons J, Tamborero D, Lopez-Bigas N, Gonzalez-Perez A.

Genome Med. 2016 Oct 3;8(1):98.

14.

A Landscape of Pharmacogenomic Interactions in Cancer.

Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, Heyn H, Deng X, Egan RK, Liu Q, Mironenko T, Mitropoulos X, Richardson L, Wang J, Zhang T, Moran S, Sayols S, Soleimani M, Tamborero D, Lopez-Bigas N, Ross-Macdonald P, Esteller M, Gray NS, Haber DA, Stratton MR, Benes CH, Wessels LFA, Saez-Rodriguez J, McDermott U, Garnett MJ.

Cell. 2016 Jul 28;166(3):740-754. doi: 10.1016/j.cell.2016.06.017. Epub 2016 Jul 7.

15.

Non-coding recurrent mutations in chronic lymphocytic leukaemia.

Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, Munar M, Rubio-Pérez C, Jares P, Aymerich M, Baumann T, Beekman R, Belver L, Carrio A, Castellano G, Clot G, Colado E, Colomer D, Costa D, Delgado J, Enjuanes A, Estivill X, Ferrando AA, Gelpí JL, González B, González S, González M, Gut M, Hernández-Rivas JM, López-Guerra M, Martín-García D, Navarro A, Nicolás P, Orozco M, Payer ÁR, Pinyol M, Pisano DG, Puente DA, Queirós AC, Quesada V, Romeo-Casabona CM, Royo C, Royo R, Rozman M, Russiñol N, Salaverría I, Stamatopoulos K, Stunnenberg HG, Tamborero D, Terol MJ, Valencia A, López-Bigas N, Torrents D, Gut I, López-Guillermo A, López-Otín C, Campo E.

Nature. 2015 Oct 22;526(7574):519-24. doi: 10.1038/nature14666. Epub 2015 Jul 22.

PMID:
26200345
16.

In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities.

Rubio-Perez C, Tamborero D, Schroeder MP, Antolín AA, Deu-Pons J, Perez-Llamas C, Mestres J, Gonzalez-Perez A, Lopez-Bigas N.

Cancer Cell. 2015 Mar 9;27(3):382-96. doi: 10.1016/j.ccell.2015.02.007.

17.

Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes.

Leiserson MD, Vandin F, Wu HT, Dobson JR, Eldridge JV, Thomas JL, Papoutsaki A, Kim Y, Niu B, McLellan M, Lawrence MS, Gonzalez-Perez A, Tamborero D, Cheng Y, Ryslik GA, Lopez-Bigas N, Getz G, Ding L, Raphael BJ.

Nat Genet. 2015 Feb;47(2):106-14. doi: 10.1038/ng.3168. Epub 2014 Dec 15.

18.

Fast randomization of large genomic datasets while preserving alteration counts.

Gobbi A, Iorio F, Dawson KJ, Wedge DC, Tamborero D, Alexandrov LB, Lopez-Bigas N, Garnett MJ, Jurman G, Saez-Rodriguez J.

Bioinformatics. 2014 Sep 1;30(17):i617-23. doi: 10.1093/bioinformatics/btu474.

19.

OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action.

Schroeder MP, Rubio-Perez C, Tamborero D, Gonzalez-Perez A, Lopez-Bigas N.

Bioinformatics. 2014 Sep 1;30(17):i549-55. doi: 10.1093/bioinformatics/btu467.

20.

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin.

Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MDM, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA; Cancer Genome Atlas Research Network, Benz CC, Perou CM, Stuart JM.

Cell. 2014 Aug 14;158(4):929-944. doi: 10.1016/j.cell.2014.06.049. Epub 2014 Aug 7.

21.

Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia.

Ferreira PG, Jares P, Rico D, Gómez-López G, Martínez-Trillos A, Villamor N, Ecker S, González-Pérez A, Knowles DG, Monlong J, Johnson R, Quesada V, Djebali S, Papasaikas P, López-Guerra M, Colomer D, Royo C, Cazorla M, Pinyol M, Clot G, Aymerich M, Rozman M, Kulis M, Tamborero D, Gouin A, Blanc J, Gut M, Gut I, Puente XS, Pisano DG, Martin-Subero JI, López-Bigas N, López-Guillermo A, Valencia A, López-Otín C, Campo E, Guigó R.

Genome Res. 2014 Feb;24(2):212-26. doi: 10.1101/gr.152132.112. Epub 2013 Nov 21.

22.

Comprehensive identification of mutational cancer driver genes across 12 tumor types.

Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C, Reimand J, Lawrence MS, Getz G, Bader GD, Ding L, Lopez-Bigas N.

Sci Rep. 2013 Oct 2;3:2650. doi: 10.1038/srep02650.

23.

IntOGen-mutations identifies cancer drivers across tumor types.

Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Tamborero D, Schroeder MP, Jene-Sanz A, Santos A, Lopez-Bigas N.

Nat Methods. 2013 Nov;10(11):1081-2. doi: 10.1038/nmeth.2642. Epub 2013 Sep 15.

24.

OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes.

Tamborero D, Gonzalez-Perez A, Lopez-Bigas N.

Bioinformatics. 2013 Sep 15;29(18):2238-44. doi: 10.1093/bioinformatics/btt395. Epub 2013 Jul 24.

PMID:
23884480
25.

Oncodrive-CIS: a method to reveal likely driver genes based on the impact of their copy number changes on expression.

Tamborero D, Lopez-Bigas N, Gonzalez-Perez A.

PLoS One. 2013;8(2):e55489. doi: 10.1371/journal.pone.0055489. Epub 2013 Feb 8.

26.

Effect of repeated radiofrequency catheter ablation on left atrial function for the treatment of atrial fibrillation.

Montserrat S, Sitges M, Calvo N, Silva E, Tamborero D, Vidal B, Berruezo A, Bernado C, Mont L, Brugada J.

Am J Cardiol. 2011 Dec 15;108(12):1741-6. doi: 10.1016/j.amjcard.2011.07.041. Epub 2011 Sep 8.

PMID:
21906703
27.

Electrocardiographic versus echocardiographic optimization of the interventricular pacing delay in patients undergoing cardiac resynchronization therapy.

Tamborero D, Vidal B, Tolosana JM, Sitges M, Berruezo A, Silva E, Castel M, Matas M, Arbelo E, Rios J, Villacastín J, Brugada J, Mont L.

J Cardiovasc Electrophysiol. 2011 Oct;22(10):1129-34. doi: 10.1111/j.1540-8167.2011.02085.x. Epub 2011 Jun 2.

PMID:
21635609
28.

Comparison of hemodynamic versus dyssynchrony assessment for interventricular delay optimization with echocardiography in cardiac resynchronization therapy.

Doltra A, Vidal B, Silva E, Mont L, Tamborero D, Castel MÁ, Tolosana JM, Berruezo A, Brugada J, Sitges M.

Pacing Clin Electrophysiol. 2011 Aug;34(8):984-90. doi: 10.1111/j.1540-8159.2011.03078.x. Epub 2011 Mar 25.

PMID:
21438894
29.

Usefulness of transoesophageal echocardiography before circumferential pulmonary vein ablation in patients with atrial fibrillation: is it really mandatory?

Calvo N, Mont L, Vidal B, Nadal M, Montserrat S, Andreu D, Tamborero D, Pare C, Azqueta M, Berruezo A, Brugada J, Sitges M.

Europace. 2011 Apr;13(4):486-91. doi: 10.1093/europace/euq456. Epub 2010 Dec 24.

PMID:
21186230
30.

Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment.

Castel MA, Magnani S, Mont L, Roig E, Tamborero D, Méndez-Zurita F, Femenia JF, Tolosana JM, Pérez-Villa F, Brugada J.

Europace. 2010 Aug;12(8):1136-40. doi: 10.1093/europace/euq163. Epub 2010 Jun 12.

PMID:
20543199
31.

Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients.

Matiello M, Nadal M, Tamborero D, Berruezo A, Montserrat J, Embid C, Rios J, Villacastín J, Brugada J, Mont L.

Europace. 2010 Aug;12(8):1084-9. doi: 10.1093/europace/euq128. Epub 2010 May 20.

PMID:
20488856
32.

Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): an independent predictor of poor response to cardiac resynchronization therapy.

Tolosana JM, Mont L, Sitges M, Berruezo A, Delgado V, Vidal B, Tamborero D, Morales M, Batlle M, Roig E, Castel MA, Pérez-Villa F, Godoy M, Brugada J.

Eur J Heart Fail. 2010 May;12(5):492-8. doi: 10.1093/eurjhf/hfq037. Epub 2010 Apr 1.

33.

Effects of adipose tissue-derived stem cell therapy after myocardial infarction: impact of the route of administration.

Rigol M, Solanes N, Farré J, Roura S, Roqué M, Berruezo A, Bellera N, Novensà L, Tamborero D, Prat-Vidal C, Huzman MA, Batlle M, Hoefsloot M, Sitges M, Ramírez J, Dantas AP, Merino A, Sanz G, Brugada J, Bayés-Genís A, Heras M.

J Card Fail. 2010 Apr;16(4):357-66. doi: 10.1016/j.cardfail.2009.12.006. Epub 2010 Feb 9.

PMID:
20350704
34.

Circumferential pulmonary vein ablation: does use of a circular mapping catheter improve results? A prospective randomized study.

Tamborero D, Mont L, Berruezo A, Guasch E, Rios J, Nadal M, Matiello M, Andreu D, Sitges M, Brugada J.

Heart Rhythm. 2010 May;7(5):612-8. doi: 10.1016/j.hrthm.2010.01.021. Epub 2010 Jan 22.

PMID:
20193794
35.

Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes.

Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E, Nadal M, Andreu D, Vidal B, Sitges M, Brugada J.

Europace. 2010 Jan;12(1):30-6. doi: 10.1093/europace/eup320.

36.

Optimization of the interventricular delay in cardiac resynchronization therapy using the QRS width.

Tamborero D, Mont L, Sitges M, Silva E, Berruezo A, Vidal B, Delgado V, Tolosana JM, Godoy M, Castel A, Brugada J.

Am J Cardiol. 2009 Nov 15;104(10):1407-12. doi: 10.1016/j.amjcard.2009.07.006.

PMID:
19892059
37.

Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation.

De Potter T, Berruezo A, Mont L, Matiello M, Tamborero D, Santibañez C, Benito B, Zamorano N, Brugada J.

Europace. 2010 Jan;12(1):24-9. doi: 10.1093/europace/eup309.

38.

Midterm 'super-response' to cardiac resynchronization therapy by biventricular pacing with fusion: insights from electro-anatomical mapping.

Vatasescu R, Berruezo A, Mont L, Tamborero D, Sitges M, Silva E, Tolosana JM, Vidal B, Andreu D, Brugada J.

Europace. 2009 Dec;11(12):1675-82. doi: 10.1093/europace/eup333. Epub 2009 Oct 31.

39.

Noninvasive evaluation of radiofrequency lesions in the human ventricular myocardium by contrast-enhanced cardiac magnetic resonance.

Berruezo A, Ortiz-Pérez JT, Guasch E, Tamborero D, Silva E, de Caralt TM, Perea RJ, Boussy T, Mont L, Brugada J.

Circ Arrhythm Electrophysiol. 2009 Apr;2(2):208-11. doi: 10.1161/CIRCEP.108.817353. No abstract available.

PMID:
19808466
40.

Left atrial posterior wall isolation does not improve the outcome of circumferential pulmonary vein ablation for atrial fibrillation: a prospective randomized study.

Tamborero D, Mont L, Berruezo A, Matiello M, Benito B, Sitges M, Vidal B, de Caralt TM, Perea RJ, Vatasescu R, Brugada J.

Circ Arrhythm Electrophysiol. 2009 Feb;2(1):35-40. doi: 10.1161/CIRCEP.108.797944. Epub 2008 Dec 3.

PMID:
19808442
41.

Quantification of left ventricular asynchrony throughout the whole cardiac cycle with a computed algorithm: application for optimizing resynchronization therapy.

Silva E, Sitges M, Mont L, Delgado V, Tamborero D, Vidal B, Godoy M, Poyatos S, Pare C, Azqueta M, Brugada J.

J Cardiovasc Electrophysiol. 2009 Oct;20(10):1130-6. doi: 10.1111/j.1540-8167.2009.01507.x. Epub 2009 Jun 2.

PMID:
19549037
42.

Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial.

Tolosana JM, Berne P, Mont L, Heras M, Berruezo A, Monteagudo J, Tamborero D, Benito B, Brugada J.

Eur Heart J. 2009 Aug;30(15):1880-4. doi: 10.1093/eurheartj/ehp194. Epub 2009 May 31.

43.

Electrocardiographic optimization of cardiac resynchronization devices: simple, but not so simple!

Mont L, Sitges M, Delgado V, Vidal B, Tamborero D, Brugada J.

Am J Cardiol. 2009 Mar 15;103(6):894. doi: 10.1016/j.amjcard.2008.12.023. No abstract available.

PMID:
19268755
44.

Six-minute walking test predicts long-term cardiac death in patients who received cardiac resynchronization therapy.

Castel MA, Méndez F, Tamborero D, Mont L, Magnani S, Tolosana JM, Berruezo A, Godoy M, Sitges M, Vidal B, Roig E, Brugada J.

Europace. 2009 Mar;11(3):338-42. doi: 10.1093/europace/eun362. Epub 2009 Jan 9.

PMID:
19136491
45.

Gender differences in clinical manifestations of Brugada syndrome.

Benito B, Sarkozy A, Mont L, Henkens S, Berruezo A, Tamborero D, Arzamendi D, Berne P, Brugada R, Brugada P, Brugada J.

J Am Coll Cardiol. 2008 Nov 4;52(19):1567-73. doi: 10.1016/j.jacc.2008.07.052.

46.

Comparison of benefits and mortality in cardiac resynchronization therapy in patients with atrial fibrillation versus patients in sinus rhythm (Results of the Spanish Atrial Fibrillation and Resynchronization [SPARE] Study).

Tolosana JM, Hernandez Madrid A, Brugada J, Sitges M, Garcia Bolao I, Fernandez Lozano I, Martinez Ferrer J, Quesada A, Macias A, Marin W, Escudier JM, Gomez AA, Gimenez Alcala M, Tamborero D, Berruezo A, Mont L; SPARE Investigators.

Am J Cardiol. 2008 Aug 15;102(4):444-9. doi: 10.1016/j.amjcard.2008.04.008. Epub 2008 May 22.

PMID:
18678303
47.

Cooled-tip vs. 8 mm-tip catheter for circumferential pulmonary vein ablation: comparison of efficacy, safety, and lesion extension.

Matiello M, Mont L, Tamborero D, Berruezo A, Benito B, Gonzalez E, Brugada J.

Europace. 2008 Aug;10(8):955-60. doi: 10.1093/europace/eun144. Epub 2008 May 29.

PMID:
18515285
48.

Fate of left atrial function as determined by real-time three-dimensional echocardiography study after radiofrequency catheter ablation for the treatment of atrial fibrillation.

Delgado V, Vidal B, Sitges M, Tamborero D, Mont L, Berruezo A, Azqueta M, Paré C, Brugada J.

Am J Cardiol. 2008 May 1;101(9):1285-90. doi: 10.1016/j.amjcard.2007.12.028. Epub 2008 Mar 7.

PMID:
18435959
49.

Left atrial contractility is preserved after successful circumferential pulmonary vein ablation in patients with atrial fibrillation.

Perea RJ, Tamborero D, Mont L, De Caralt TM, Ortiz JT, Berruezo A, Matiello M, Sitges M, Vidal B, Sanchez M, Brugada J.

J Cardiovasc Electrophysiol. 2008 Apr;19(4):374-9. doi: 10.1111/j.1540-8167.2007.01086.x. Epub 2008 Feb 4.

PMID:
18266672
50.

Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals.

Mont L, Tamborero D, Elosua R, Molina I, Coll-Vinent B, Sitges M, Vidal B, Scalise A, Tejeira A, Berruezo A, Brugada J; GIRAFA (Grup Integrat de Recerca en Fibril-lació Auricular) Investigators.

Europace. 2008 Jan;10(1):15-20. doi: 10.1093/europace/eum263. Epub 2008 Jan 4.

PMID:
18178694

Supplemental Content

Loading ...
Support Center